VinaR - Repozitorijum Instituta za nuklearne nauke Vinča
    • English
    • Српски
    • Српски (Serbia)
  • Srpski (latinica) 
    • Engleski
    • Srpski (ćirilica)
    • Srpski (latinica)
  • Prijava
Pregled zapisa 
  •   VinaR
  • Vinča
  • Radovi istraživača
  • Pregled zapisa
  •   VinaR
  • Vinča
  • Radovi istraživača
  • Pregled zapisa
JavaScript is disabled for your browser. Some features of this site may not work without it.

Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination

Thumbnail
2023
Preuzimanje 🢃
Main article [PDF] (1.183Mb)
Autori
Đukić, Ivana
Kaličanin, Nevena
Senćanski, Milan V.
Pajović, Snežana B.
Milićević, Jelena S.
Prljić, Jelena
Paessler, Slobodan
Prodanović, Radivoje
Glišić, Sanja
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentu
Apstrakt
Drug resistance is a critical problem in health care that affects therapy outcomes and requires new approaches to drugdesign. SARS-CoV-2 Mpro mutations are of concern as they can potentially reduce therapeutic efficacy. Viral infections are amongst themany disorders for which nutraceuticals have been employed as an adjunct therapy. The aim of this study was to examine the potentialin vitro activity of L-arginine and vitamin C against SARS-CoV-2 Mpro. Methods: The Mpro inhibition assay was developed by cloning,expression, purification, and characterization of Mpro. Selected compounds were then screened for protease inhibition. Results: Largininewas found to be active against SARS-CoV-2 Mpro, while a vitamin C/L-arginine combination had a synergistic antiviral actionagainst Mpro. These findings confirm the results of our previous in silico repurposing study that showed L-arginine and vitamin C werepotential Mpro inhibitors. Moreover, they suggest a possible molecular mechanism to explain... the beneficial effect of arginine in COVIDpatients. Conclusions: The findings of the current study are important because they help to identify COVID-19 treatments that areefficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategyfor COVID-19 that could be used in conjunction with pharmacological agents.

Ključne reči:
anti SARS-CoV-2 / Mpro / COVID-19 / arginine / vitamin C/arginine combination / Mpro candidate inhibitors
Izvor:
Frontiers in Bioscience - Landmark, 2023, 28, 1, 8-
Finansiranje / projekti:
  • 2023-07-17 COVIDTARGET – Repurposing of drugs for prevention and treatment of Covid-19 (RS-ScienceFundRS-Fond_2020_COVID19-7551100)

DOI: 10.31083/j.fbl2801008

ISSN: 2768-6698

PubMed: 36722278

WoS: 000964361600008

Scopus: 2-s2.0-85147187139
[ Google Scholar ]
URI
https://vinar.vin.bg.ac.rs/handle/123456789/10629
Kolekcije
  • 090 - Laboratorija za molekularnu biologiju i endokrinologiju
  • 180 - Laboratorija za bioinformatiku i računarsku hemiju
  • Radovi istraživača
Institucija/grupa
Vinča
TY  - JOUR
AU  - Đukić, Ivana
AU  - Kaličanin, Nevena
AU  - Senćanski, Milan V.
AU  - Pajović, Snežana B.
AU  - Milićević, Jelena S.
AU  - Prljić, Jelena
AU  - Paessler, Slobodan
AU  - Prodanović, Radivoje
AU  - Glišić, Sanja
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10629
AB  - Drug resistance is a critical problem in health care that affects therapy outcomes and requires new approaches to drugdesign. SARS-CoV-2 Mpro mutations are of concern as they can potentially reduce therapeutic efficacy. Viral infections are amongst themany disorders for which nutraceuticals have been employed as an adjunct therapy. The aim of this study was to examine the potentialin vitro activity of L-arginine and vitamin C against SARS-CoV-2 Mpro. Methods: The Mpro inhibition assay was developed by cloning,expression, purification, and characterization of Mpro. Selected compounds were then screened for protease inhibition. Results: Largininewas found to be active against SARS-CoV-2 Mpro, while a vitamin C/L-arginine combination had a synergistic antiviral actionagainst Mpro. These findings confirm the results of our previous in silico repurposing study that showed L-arginine and vitamin C werepotential Mpro inhibitors. Moreover, they suggest a possible molecular mechanism to explain the beneficial effect of arginine in COVIDpatients. Conclusions: The findings of the current study are important because they help to identify COVID-19 treatments that areefficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategyfor COVID-19 that could be used in conjunction with pharmacological agents.
T2  - Frontiers in Bioscience - Landmark
T1  - Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination
VL  - 28
IS  - 1
SP  - 8
DO  - 10.31083/j.fbl2801008
ER  - 
@article{
author = "Đukić, Ivana and Kaličanin, Nevena and Senćanski, Milan V. and Pajović, Snežana B. and Milićević, Jelena S. and Prljić, Jelena and Paessler, Slobodan and Prodanović, Radivoje and Glišić, Sanja",
year = "2023",
abstract = "Drug resistance is a critical problem in health care that affects therapy outcomes and requires new approaches to drugdesign. SARS-CoV-2 Mpro mutations are of concern as they can potentially reduce therapeutic efficacy. Viral infections are amongst themany disorders for which nutraceuticals have been employed as an adjunct therapy. The aim of this study was to examine the potentialin vitro activity of L-arginine and vitamin C against SARS-CoV-2 Mpro. Methods: The Mpro inhibition assay was developed by cloning,expression, purification, and characterization of Mpro. Selected compounds were then screened for protease inhibition. Results: Largininewas found to be active against SARS-CoV-2 Mpro, while a vitamin C/L-arginine combination had a synergistic antiviral actionagainst Mpro. These findings confirm the results of our previous in silico repurposing study that showed L-arginine and vitamin C werepotential Mpro inhibitors. Moreover, they suggest a possible molecular mechanism to explain the beneficial effect of arginine in COVIDpatients. Conclusions: The findings of the current study are important because they help to identify COVID-19 treatments that areefficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategyfor COVID-19 that could be used in conjunction with pharmacological agents.",
journal = "Frontiers in Bioscience - Landmark",
title = "Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination",
volume = "28",
number = "1",
pages = "8",
doi = "10.31083/j.fbl2801008"
}
Đukić, I., Kaličanin, N., Senćanski, M. V., Pajović, S. B., Milićević, J. S., Prljić, J., Paessler, S., Prodanović, R.,& Glišić, S.. (2023). Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination. in Frontiers in Bioscience - Landmark, 28(1), 8.
https://doi.org/10.31083/j.fbl2801008
Đukić I, Kaličanin N, Senćanski MV, Pajović SB, Milićević JS, Prljić J, Paessler S, Prodanović R, Glišić S. Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination. in Frontiers in Bioscience - Landmark. 2023;28(1):8.
doi:10.31083/j.fbl2801008 .
Đukić, Ivana, Kaličanin, Nevena, Senćanski, Milan V., Pajović, Snežana B., Milićević, Jelena S., Prljić, Jelena, Paessler, Slobodan, Prodanović, Radivoje, Glišić, Sanja, "Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination" in Frontiers in Bioscience - Landmark, 28, no. 1 (2023):8,
https://doi.org/10.31083/j.fbl2801008 . .

DSpace software copyright © 2002-2015  DuraSpace
O repozitorijumu VinaR | Pošaljite zapažanja

re3dataOpenAIRERCUB
 

 

Kompletan repozitorijumGrupeAutoriNasloviTemeOva institucijaAutoriNasloviTeme

Statistika

Pregled statistika

DSpace software copyright © 2002-2015  DuraSpace
O repozitorijumu VinaR | Pošaljite zapažanja

re3dataOpenAIRERCUB